A Prospective Study of the Effects of Radioiodine Therapy for Hyperthyroidism in Patients With Minimally Active Graves' Ophthalmopathy | oneGRAVESvoice
Global Search
Global Search

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Back to Evidence & Education / Scientific Articles

A Prospective Study of the Effects of Radioiodine Therapy for Hyperthyroidism in Patients With Minimally Active Graves’ Ophthalmopathy

key information

source: The Journal of Clinical Endocrinology and Metabolism

year: 2005

authors: Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J

summary/abstract:

Context:
Radioiodine is an effective and safe treatment for hyperthyroidism but has been implicated as a risk factor for deterioration or new presentation of Graves’ ophthalmopathy (GO). Prophylactic glucocorticoids appear to prevent this effect.

Objective:
The objective of this study was to document the course of GO after radioiodine therapy.

Design:
This was a prospective observational study. Patients were assessed at baseline and 2, 4, 6, and 12 months after radioiodine therapy.

Setting:
The study was conducted at a tertiary referral center.

Patients:
Seventy-two GO patients with minimally active eye disease participated in the study.

Intervention:
A fixed dose of radioiodine was administered. T(4) was commenced 2 wk later to prevent hypothyroidism.

Main Outcome Measures:
Change in activity and severity of GO were analyzed.

Results:
Exophthalmometer readings, the width of the palpebral aperture, diplopia scores, and the clinical activity score improved significantly. By clinically significant criteria, the eye disease improved in four patients (transiently in three of the four cases), most likely attributable to the natural course of the disease. No patient’s eyes deteriorated.

Conclusions:
Radioiodine is not associated with deterioration of GO in patients with minimally active eye disease when postradioiodine hypothyroidism is prevented.

organization: Freeman Hospital, UK

DOI: 10.1210/jc.2005-0507

read more full text

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Powered by

Brought to you by

Supported through an independent
educational grant by

© 2022 rareLife solutions Inc.